Scribd Logo
Upload

Welcome to Scribd!

  • 21 views

    Folfirinox Annals 2016

    Uploaded by

    Mahesh Tamhane
    1) This study examined the use of FOLFIRINOX chemotherapy with or without chemoradiotherapy (CRT) followed by surgery for patients with initially non-resectable pancreatic cancer. 2) Between 2012-present, 59 patients received FOLFIRINOX, with 16 patients subsequently having tumors resected after CRT. 3) Median survival was 21.1 months for all patients and had not yet been reached for resected patients, compared to 14.1 months for non-resected patients. FOLFIRINOX showed acceptable toxicity.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Folfirinox Annals 2016

    Uploaded by

    Mahesh Tamhane
    21 views1 page
    1) This study examined the use of FOLFIRINOX chemotherapy with or without chemoradiotherapy (CRT) followed by surgery for patients with initially non-resectable pancreatic cancer. 2) Between 2012-present, 59 patients received FOLFIRINOX, with 16 patients subsequently having tumors resected after CRT. 3) Median survival was 21.1 months for all patients and had not yet been reached for resected patients, compared to 14.1 months for non-resected patients. FOLFIRINOX showed acceptable toxicity.

    Original Title

    FOLFIRINOX ANNALS 2016

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    1) This study examined the use of FOLFIRINOX chemotherapy with or without chemoradiotherapy (CRT) followed by surgery for patients with initially non-resectable pancreatic cancer. 2) Between 2012-present, 59 patients received FOLFIRINOX, with 16 patients subsequently having tumors resected after CRT. 3) Median survival was 21.1 months for all patients and had not yet been reached for resected patients, compared to 14.1 months for non-resected patients. FOLFIRINOX showed acceptable toxicity.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    21 views1 page

    Folfirinox Annals 2016

    Uploaded by

    Mahesh Tamhane
    1) This study examined the use of FOLFIRINOX chemotherapy with or without chemoradiotherapy (CRT) followed by surgery for patients with initially non-resectable pancreatic cancer. 2) Between 2012-present, 59 patients received FOLFIRINOX, with 16 patients subsequently having tumors resected after CRT. 3) Median survival was 21.1 months for all patients and had not yet been reached for resected patients, compared to 14.1 months for non-resected patients. FOLFIRINOX showed acceptable toxicity.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 1

    Annals of Oncology 27 (Supplement 6): vi207–vi242, 2016

    doi:10.1093/annonc/mdw371.72

    series the patients were evaluated and offered CRT (50.4 Gy/27F & capecitabine) if
    gastrointestinal tumours, deemed potentially resectable. Resections were performed if deemed possible by the
    non-colorectal MDT.
    Results: Between August 2012 and present, 59 patients have been recruited with a
    median observation time of 17.4 months. Median age was 65(range 38-75) years, with
    40%/60% stage II/III distribution. Median CA19-9 was 268(range 1-13,432).
    680P Chemotherapy for patients with non-resectable pancreatic Three-hundred-sixty-two courses of FOLFIRINOX have been given, with a median of
    cancer with additional chemo-radiotherapy for patients with 6.0 per patient, with a median of 2 without dose modifications. Presently twenty-two
    potentially resectable tumours: Final results patients have been treated with CRT. Six-teen patients have been resected, of which 8
    received prior CRT. Median survival for all patients was 21.1 months (14-NR) with a
    P. Pfeiffer1, M. Ladekarl2, M.B. Mortensen3, A-L. Fromm4, J.K. Bjerregaard1 1-year survival of 74% (58-85). For patients not resected the median survival was 14.1
    1
    Department of Oncology, Odense University Hospital, Odense, Denmark, months (10-16) for resected the median survival has not yet been reached. The
    2
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark, FOLFIRINOX was associated with adverse events similar to what is expected in
    3
    Department of Surgery, Odense University Hospital, Odense, Denmark, metastatic patients.
    4
    Department of Oncology, University Hospital Herlev, Herlev, Denmark Conclusions: FOLFIRINOX with or without CRT in patients with LAPC shows
    promising efficacy in patients with both borderline and never-resectable tumors.
    Background: Locally advanced pancreatic cancer (LAPC) is often a mix of borderline Unmodified FOLFIRINOX had acceptable toxicity, however dose reductions are often
    and never-resectable tumors. Multimodality treatment might downstage these tumors needed. CRT following initial FOLFIRINOX was feasible and without unexpected

    Downloaded from http://annonc.oxfordjournals.org/ by guest on October 17, 2016


    to allow a potential radical resection, especially the borderline group. In this ongoing toxicity.
    phase II study we examined the feasibility of FOLFIRINOX with or without CRT Clinical trial identification: NCT-01397019
    followed by surgery for both borderline and never-resectable tumors (NCT-01397019).
    Legal entity responsible for the study: N/A
    Methods: Patients in performance status 0-1, with initially non-resectable stage II/III
    pancreatic cancer were offered FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 Funding: Danish Pancreatic Cancer Group
    mg/m2, leucovorin 400 mg/m2, 5FU 400 mg/m2+ 2400 mg/m2) every 14 days. Every 4th Disclosure: All authors have declared no conflicts of interest.

    abstracts

    © European Society for Medical Oncology 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
    All rights reserved. For permissions, please email: [email protected].

    You might also like